Mariagrazia Distefano, Anna Fagotti, Gabriella Ferrandina, Francesco Fanfani, Daniela Smaniotto, Giuseppe D'Agostino, Alessio Morganti, Giovanni Scambia
Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S166-70. doi: 10.1016/j.ygyno.2005.07.074. Epub 2005 Sep 8.
To demonstrate the efficacy and feasibility of preoperative chemoradiotherapy in a consecutive series of 100 locally advanced cervical cancer (LACC) patients.
Between October 1997 and December 2004, 100 LACC patients were consecutively staged and treated at the Catholic University of the Sacred Heart of Rome. Radiotherapy was administered to the whole pelvic region (1.8 Gy/day, totaling 39.6 Gy) in combination with cisplatin (20 mg/m(2)) and 5-FU (1000 mg/m(2)) (both on days 1-4 and 27-30). Radical surgery was performed 5-6 weeks after the end of the treatment.
A clinical complete or partial response was observed in 96 patients (56 and 40, respectively). Radical surgery was performed in 95 patients and an overall complication rate of 12.6% was observed in the early postoperative time. At pathological examination, 43 of 95 patients (45.2%) undergoing radical surgery showed complete response to treatment, 28 patients (29.5%) only had a microscopic disease, 18 patients (19%) had a partial response and 6 (6.3%) had no change of disease. With a median follow-up time of 25 months, the 5-year disease-free survival was 76% and the 5-year overall survival was 78%.
These data confirm the possibility of achieving encouraging rates of local control and OS in LACC patients submitted to chemoradiation plus surgery, with a low rate of toxicity and complications.
在连续的100例局部晚期宫颈癌(LACC)患者中证明术前放化疗的疗效和可行性。
1997年10月至2004年12月,100例LACC患者在罗马圣心天主教大学连续进行分期和治疗。对整个盆腔区域进行放疗(1.8 Gy/天,共39.6 Gy),同时联合顺铂(20 mg/m²)和5-氟尿嘧啶(1000 mg/m²)(均在第1 - 4天和第27 - 30天使用)。治疗结束后5 - 6周进行根治性手术。
96例患者观察到临床完全或部分缓解(分别为56例和40例)。95例患者进行了根治性手术,术后早期总体并发症发生率为12.6%。病理检查显示,95例接受根治性手术的患者中,43例(45.2%)对治疗显示完全缓解,28例(29.5%)仅存在微小病灶,18例(19%)有部分缓解,6例(6.3%)疾病无变化。中位随访时间为25个月,5年无病生存率为76%,5年总生存率为78%。
这些数据证实,对于接受放化疗加手术的LACC患者,有可能获得令人鼓舞的局部控制率和总生存率,且毒性和并发症发生率较低。